Table 2.
Examples of ongoing phase 3 studies in youth with T2D (as of 30 April 2015)
| Drug | Trial indentifer | Subjects (N) | Status | Duration |
|---|---|---|---|---|
| Colesevelam |
NCT01258075 |
200 |
Open |
4 years, 5 months |
| Exenatide |
NCT00658021 |
195 |
Open |
6 years, 11 months |
| Linagliptin |
NCT01342484 |
117 |
Open |
4 years |
| Liraglutide |
NCT01541215 |
172 |
Open |
2 years, 5 months |
| Saxagliptin |
NCT01434186 |
224 |
Open |
3 years, 5 months |
| Saxagliptin |
NCT01204775 |
136 |
Open |
3 years, 10 months |
| Sitagliptin |
NCT01485614 |
170 |
Open |
3 years, 2 months |
| Sitagliptin |
NCT01472367 |
90 |
Open |
3 years, 4 months |
| Sitagliptin | NCT01760447 | 90 | Open | 2 years, 2 months |